Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche, Seaside collaborate on Fragile X and autism disorders; terminated

Executive Summary

Seaside Therapeutics LLC (neurodevelopmental diseases caused by single-gene mutations) has exclusively licensed Roche patents related to metabotropic glutamate receptor subtype 5 (mGluR5) antagonists for brain development disorders. The Big Pharma also received an option on Seaside’s gamma-aminobutyric acid type B (GABA-B) agonist STX209 (arbaclofen), in Phase III for Fragile X syndrome (FXS) and Phase II for autism spectrum disorders (ASD).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register